Libertine Holdings initiates strategic review to maximize stakeholder value

TAGS

The board of directors of Libertine Holdings PLC, known for its development of Linear Generator technology, has announced the commencement of a formal review to explore strategic options aimed at maximizing value for its shareholders, employees, and other stakeholders. This Strategic Review comes at a crucial time as the company seeks additional resources to advance its innovative technology into full commercialization.

Since its initial public offering in December 2021, Libertine Holdings has made significant progress, particularly with its HEXAGEN™ technology platform, which was successfully integrated and demonstrated in collaboration with Hyliion Holdings Corp. However, despite these technical advancements and positive market interest, further investment is necessary to move these technologies from the development phase into customer programs.

See also  Cupid Limited reassesses investment strategy, withdraws from TFCI plans

The Strategic Review will consider a range of options, including potential equity raises, strategic partnerships, or even a sale of the company. Currently, no decisions have been made, and there is no certainty that this review will result in any specific transaction. The possibility of Libertine remaining an independent publicly listed entity is just one of the scenarios being evaluated.

The review process, guided by the City Code on Takeovers and Mergers, will also explore the sale of the company or parts of its intellectual property, specifically the HEXAGEN technology platform. This process, known as the “Formal Sale Process,” is designed to ensure fairness and transparency in any potential sale or partnership discussions.

See also  Chariot Limited undertakes strategic review of transitional power division

Libertine Holdings operates in a dynamic market with growing demand for its dispatchable power generation and vehicle application technologies. The company has recently signed strategic partnerships that are expected to support business development and pilot program delivery in the fiscal year 2025.

As Libertine Holdings evaluates its strategic options, the company remains committed to leveraging its technical advancements to secure a sustainable and profitable future. This review is not only a reflection of the challenges faced in scaling high-tech innovations but also an opportunity to strategically position the company for long-term success.

See also  Biocon and Biomm ink exclusive deal to bring Semaglutide to Brazil

Panmure Gordon (UK) Limited has been appointed as the financial advisor for the Formal Sale Process. Interested parties are invited to express their interest through Panmure Gordon, following which they may gain access to detailed company information to form their proposals.

The outcomes of this Strategic Review are set to define the future path for Libertine Holdings, with potential significant implications for its technology deployment and market expansion strategies. The company has reassured that any significant developments or changes resulting from this review will be promptly communicated to the market.

CATEGORIES
TAGS
Share This